Oct 6, 2003
Why don't you ever hear anything about Rescriptor? It is an approved NNRTI but no one ever mentions it. Is anyone on this drug?
Response from Dr. Pierone
The reason that this medication is not often mentioned is that it used very much anymore. It is easier to use nevirapine (Viramune) or efavirenz (Sustiva) in the NNRTI class. Rescriptor is 6 pills per day (3 - 200mg tablets twice daily) and competes against one Sustiva or two Viramune a day.
Also, if someone develops resistance to Viramune or Sustiva they usually develop cross-resistance to Rescriptor even though they had never been exposed to Rescriptor. This limits its use in a salvage scenario. We used to use Resciptor with Crixivan in the past because of an interaction that led to higher levels of Crixivan.
Having said this, I still have a few patients on it (from the olden days) and they are doing well. They have undetectable viral load, have their medicine-taking routine down, and don't want to rock the boat and risk exposure to an alternative medication.
Get Email Notifications When This Forum Updates or Subscribe With RSS
- Anal Warts After Sex With Sex Worker Worried I Have HIV
- Blisters After Kissing Cut On Lip Worried I Have HIV
- Bloody Nose After Sex With Stripper Worried I Have HIV
- Itchy Red Spots After Genital Rubbing Sign Of HIV AIDS
- Pain In Penis After Open Mouth Kissing What Are The Chances Of HIV
- Painful Red Spots After Having Sex During Period Worried I Have HIV
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.